INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 184 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2020. The put-call ratio across all filers is 1.12 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $551 | +8.7% | 41,037 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $507 | -99.9% | 41,037 | -28.3% | 0.00% | 0.0% |
| Q3 2022 | $797,000 | +169.3% | 57,195 | +166.7% | 0.00% | – |
| Q2 2022 | $296,000 | -70.5% | 21,442 | -65.2% | 0.00% | -100.0% |
| Q1 2022 | $1,002,000 | +45.0% | 61,615 | +45.2% | 0.00% | 0.0% |
| Q4 2021 | $691,000 | +265.6% | 42,421 | +454.3% | 0.00% | – |
| Q4 2020 | $189,000 | +626.9% | 7,653 | +1079.2% | 0.00% | – |
| Q3 2020 | $26,000 | -92.0% | 649 | -90.4% | 0.00% | – |
| Q2 2020 | $325,000 | +282.4% | 6,795 | +401.1% | 0.00% | – |
| Q1 2020 | $85,000 | – | 1,356 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 234,375 | $23,623,000 | 22.67% |
| Boxer Capital, LLC | 600,000 | $60,474,000 | 7.47% |
| DLD Asset Management, LP | 834,600 | $84,136,000 | 5.77% |
| GREAT POINT PARTNERS LLC | 200,000 | $20,158,000 | 2.55% |
| BB BIOTECH AG | 575,719 | $58,027,000 | 1.86% |
| Elk Creek Partners, LLC | 207,657 | $20,930,000 | 1.74% |
| ALTRINSIC GLOBAL ADVISORS LLC | 277,944 | $28,014,000 | 1.34% |
| Sarissa Capital Management LP | 54,000 | $5,442,000 | 1.21% |
| QCM Cayman, Ltd. | 2,181 | $220,000 | 0.90% |
| Opus Point Partners Management, LLC | 3,534 | $356,000 | 0.78% |